WST Stock Overview
Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
WST passed our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Shifting To Biologics And High-Value Products Spurs Remarkable Revenue And Profit Growth
West Pharmaceutical Services, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$306.73 |
| 52 Week High | US$413.70 |
| 52 Week Low | US$265.00 |
| Beta | 1.01 |
| 11 Month Change | 1.30% |
| 3 Month Change | -5.21% |
| 1 Year Change | -18.34% |
| 33 Year Change | -30.54% |
| 5 Year Change | 116.28% |
| Change since IPO | 23,986.78% |
Recent News & Updates
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20
A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02Recent updates
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Shareholder Returns
| WST | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.4% | 0.3% | 1.2% |
| 1Y | -18.3% | 11.9% | 30.2% |
Return vs Industry: WST underperformed the US Life Sciences industry which returned 11.9% over the past year.
Return vs Market: WST underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| WST volatility | |
|---|---|
| WST Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WST has not had significant price volatility in the past 3 months.
Volatility Over Time: WST's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 10,600 | Eric Green | www.westpharma.com |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
West Pharmaceutical Services, Inc. Fundamentals Summary
| WST fundamental statistics | |
|---|---|
| Market cap | US$22.35b |
| Earnings (TTM) | US$524.90m |
| Revenue (TTM) | US$2.88b |
42.4x
P/E Ratio7.7x
P/S RatioIs WST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WST income statement (TTM) | |
|---|---|
| Revenue | US$2.88b |
| Cost of Revenue | US$1.85b |
| Gross Profit | US$1.03b |
| Other Expenses | US$501.70m |
| Earnings | US$524.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.24 |
| Gross Margin | 35.68% |
| Net Profit Margin | 18.25% |
| Debt/Equity Ratio | 8.0% |
How did WST perform over the long term?
See historical performance and comparison